FDA Emergency Use Clearance to Treat High-Risk COVID-19 Patients with Bamlanivimab Monoclonal Antibody to Have Limited Availability in Texas, where only 6000 government doses expected next week Dr Houston Methodist Howard JHuang said the best chance for most patients to receive this new drug would come from clinical trials such as the phase study 2 randomized and placebo-controlled BLAZE-1, where he directs the Houston Methodist. «Even though we wanted to give it to everyone, initially there is only 300 000 doses available for the whole country under the EU», said Huang, principal investigator of the BLAZE-1 study at Houston Methodist and specialist in pulmonology of transplants.
Bamlanivimab has been shown to reduce hospitalizations and emergency room visits in patients at high risk of COVID-19 Huang says limited supply of the drug is analogous to Remdesivir's EUA last summer in which hospitals in the countries had to try to help as many COVID patients as possible with limited doses available.
Research by scientists at UCLA and colleagues at other institutions shows that people with Parkinson's disease who lack meaningful social interactions may be at increased risk for severe disease-related symptoms
Rutgers University is a clinical trial site for the phase clinical research study 3 de Janssen Pharmaceutical Companies of Johnson & Johnson to evaluate the safety and efficacy of Janssen's COVID-19 vaccine candidate
Elon Musk, CEO of Tesla Inc, has repeatedly downplayed the severity of the coronavirus since the pandemic began on Thursday, Musk said a rapid antigen test from the same machine and the same test showed he tested positive twice, then negative twice on the same day. He questioned the validity of the test by suggesting “that something extremely wrong is happening”
A new national study covering more than 50 000 people, coordinated by Columbia researchers, is underway to determine the factors that predict disease severity and the long-term health effects of COVID-19.
Journalist's PressPass is required for
access this story until the embargo expires on 18 November 2020 at 14 h 00 HNE
Newswise PressPass gives confirmed journalists access to embargoed articles
Please log in to complete a presspass request
If you have not yet registered, please register when you
complete the registration form, please identify yourself as a journalist in order to
go to presspass request form
Researchers at the Karolinska Institute in Sweden report promising results from in vitro combination therapy against COVID-19
A recent study has shown that UV light technology already used to prevent the spread of other airborne diseases in buildings has the potential to be effective against Covid-19
Newswise enables journalists to access the latest news and provides a platform for
universities, institutions and journalists to disseminate the latest news to their
Emergency use authorization, Food and Drug Administration, clinical test
News – United States – Principal Investigator for COVID-19 drug with FDA Emergency Use Clearance available to discuss limited government drug supply and ongoing clinical trials
Associated title :
– Principal Investigator for COVID-19 with FDA Emergency Use Clearance Available